THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS

THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS

Objective: The programmed cell death 1 (PD-1) receptor is an immune checkpoint receptor expressed by activated T cells. PD-1 inhibits the immune system by binding to its ligands expressed on tumor cells. Nivolumab and pembrolizumab are some of the monoclonal antibodies that inhibit the PD-1. We pres...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Veysel GOK, Firdevs AYDIN, Alper OZCAN, Ebru YILMAZ, Ekrem UNAL, Musa KARAKUKCU, Türkan PATIROGLU, Mehmet Akif OZDEMIR, Filiz KARAMAN, Orhan GORUKMEZ, Ozlem GORUKMEZ, Atil BISGIN
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/8fc9fac9b6054cc2b9b1c3e60f6e9bd4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares